Study analysis · Open Heart · 2025
People born with 'broken' PCSK9 cholesterol genes had slightly thinner neck arteries — but the effect was tiny and doesn't prove they avoid heart attacks.
A study of about 52,000 people found that PCSK9 gene variants linked to lower LDL cholesterol were also linked to slightly thinner carotid artery walls, but this doesn't prove they prevent heart attacks.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at whether certain gene variations are linked to thinner neck arteries, which can mean less heart disease risk. But because it's not a randomized experiment, it can only show a connection, not prove that the genes directly cause the change.
What’s the bottom line?
Scientists looked at four tiny gene changes in PCSK9 that lower cholesterol. They checked whether people with more of these changes had thinner carotid arteries.
How strong is this study?
The study used a very large number of people from two different groups, which makes the results more reliable. However, it only looked at people of European ancestry and measured arteries at one point in time, so we can't be sure about cause and effect.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=52128)+20/20
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. Cross-sectional design cannot establish temporal or causal relationships. Although genetic variants are randomly assigned at conception, the study is observational and cannot rule out pleiotropy, population stratification, or residual confounding. It does not use formal Mendelian randomization with instrumental variable assumptions.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding statement was included in the provided text, so potential conflicts cannot be assessed.
The provided manuscript excerpt lacks a COI/funding section. No author affiliations or industry ties are evident. The study uses public cohorts (IMPROVE, UK Biobank) and commercial ELISA kits, but no industry funding is disclosed. Absence of funding statement limits transparency.
Key takeaways
- 01
People with more cholesterol-lowering PCSK9 gene changes tended to have slightly thinner carotid artery walls.
- 02
In UK Biobank, the combined gene score was linked to thinner arteries (p<0.05) and reportedly explained about 20% of the variation in one measure; in IMPROVE, the link was seen in women but not men (p<0.05) and explained 0.3–0.4% of variation.
- 03
The R46L variant was linked to thinner arteries in UK Biobank.
- 04
No extra-cases-per-1,000 absolute risk was reported because this measured artery thickness, not heart attacks.
- 05
This is about small differences in artery wall thickness, not heart attacks or deaths.
- 06
The study did not report absolute risk (like extra cases per 1,000 people) because it did not count disease events.
- 07
So we cannot say how many heart attacks might be prevented.
Surprising findings
- The same PCSK9 genetic score explained ~20% of CC-IMT variance in UK Biobank but only 0.3–0.4% in IMPROVE women.A 20% variance explained by four common variants is extremely high for a complex trait like artery thickness, while 0.3% is more typical for a polygenic score. The discrepancy suggests model or measurement differences.
- Only one of four PCSK9 variants (R46L) reached statistical significance for LDL-C in IMPROVE.All four variants were selected for known LDL-lowering effects, yet three didn't show significant associations on their own in this cohort.
- Sex-specific associations flipped direction between cohorts, yet formal interaction tests were non-significant.It looks like a sex difference in one cohort and the opposite in another, but statistically the study says there's no robust sex difference.
Practical takeaways
Don't rush to get PCSK9 genetic testing to predict your heart risk — focus on proven factors like blood pressure, smoking, and LDL cholesterol.
This study measured artery wall thickness, not heart attacks, and the effect was modest. PCSK9 inhibitor drugs do reduce events in trials, but that's different from genetic association.
medium confidenceIf you have high LDL cholesterol, ask your doctor about proven treatments, including statins and PCSK9 inhibitors if appropriate.
The study doesn't test any drug; it only looks at naturally occurring genetic variants.
medium confidenceWhen you see headlines about 'good cholesterol genes,' remember that small changes in artery thickness may not translate into meaningful heart attack prevention.
The study didn't report absolute risk (e.g., extra cases per 1,000 people) because it didn't count clinical events.
high confidenceWhy this study matters
Genetic score linked to thinner neck arteries
A lipid-lowering allelic score (LLAS) combining four PCSK9 variants was negatively associated with common carotid intima-media thickness (CC-IMT) in IMPROVE women and in UK Biobank men/overall (p<0.05). The fixed-effects meta-analysis (n=43,404) showed consistent negative but modest effects. No absolute risk difference was reported because the outcome was continuous artery-wall thickness, not heart attacks or deaths.
It suggests a direct link between cholesterol genes and early artery changes, but the size of the benefit is unclear because the study didn't count heart attacks.
One variant stands out: R46L
The R46L variant (rs11591147-T) was significantly associated with lower LDL cholesterol and lower PCSK9 levels in IMPROVE, and with all three CC-IMT measures in UK Biobank (p<0.05). The other three PCSK9 variants showed expected directions but were not consistently significant on their own.
R46L is a well-known 'good' cholesterol variant, so this adds support to its role in early atherosclerosis.
Sex results flip between cohorts — but no real interaction
In IMPROVE, the LLAS was linked to thinner arteries in women but not men; in UK Biobank, it was linked in men and overall but not women. Formal interaction tests were non-significant, so researchers concluded no robust sex difference.
It shows how easily subgroup findings can look contradictory even when the overall statistics say there's no real difference.
Variance explained is wildly different: ~20% vs 0.3–0.4%
In UK Biobank, the LLAS reportedly explained about 20% of the variance in CC-IMTmean (R²=0.193) and 14.5% for CC-IMTmax. In IMPROVE women, it explained only 0.3–0.4% (R²=0.003–0.004). This huge gap likely reflects model differences, covariates, and sample size.
A 20% variance explained by a genetic score is implausibly high for a single gene region, so this number deserves scrutiny.
No medication interaction — but the study wasn't designed to test drugs
The association between LLAS and CC-IMT did not differ significantly by lipid-lowering medication use (p>0.05). The authors note that PCSK9 inhibitors have proven benefits in trials, but this study only looked at naturally occurring genetic variants.
It separates genetic evidence from drug evidence — a common source of confusion in headlines.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists looked at four tiny gene changes in PCSK9 that lower cholesterol. They checked whether people with more of these changes had thinner carotid arteries.
Research results
People with more cholesterol-lowering PCSK9 gene changes tended to have slightly thinner carotid artery walls. In UK Biobank, the combined gene score was linked to thinner arteries (p<0.05) and reportedly explained about 20% of the variation in one measure; in IMPROVE, the link was seen in women but not men (p<0.05) and explained 0.3–0.4% of variation. The R46L variant was linked to thinner arteries in UK Biobank. No extra-cases-per-1,000 absolute risk was reported because this measured artery thickness, not heart attacks.
What this means - more context
This is about small differences in artery wall thickness, not heart attacks or deaths. The study did not report absolute risk (like extra cases per 1,000 people) because it did not count disease events. So we cannot say how many heart attacks might be prevented.
Investigated whether genetically determined LDL-C levels, proxied by four PCSK9 variants, influence common carotid artery atherosclerosis (CC-IMT) in a high-CVD-risk cohort (IMPROVE) and a general-population cohort (UK Biobank).
In cross-sectional analyses, a PCSK9 lipid-lowering allelic score (LLAS) was negatively associated with CC-IMT in IMPROVE women and in UKB men/overall (p<0.05), with consistent negative effect estimates in a fixed-effects meta-analysis (n=43,404). R46L (rs11591147-T) was associated with CC-IMT in UKB. Effects were modest and did not differ significantly by sex or lipid-lowering medication. The study did not report absolute risk because outcomes were continuous artery-wall measures. No retraction or corrections reported.
Methods Used
Observational genetic association study: 3,040 European high-CVD-risk IMPROVE participants and 49,088 white British UK Biobank participants; four PCSK9 variants genotyped and combined into an unweighted LLAS; carotid ultrasound measured CC-IMTmean, CC-IMTmax, CC-IMTmean-max; linear regression adjusted for age, sex, population structure, and lipid-lowering medication; fixed-effects meta-analysis of two cohorts.
Main Finding
The LLAS was negatively associated with all CC-IMT measures in IMPROVE women but not men, and in UKB men and overall (p<0.05); in UKB, LLAS reportedly explained ~20% of variance in CC-IMTmean (R2=0.193), ~18.7% in CC-IMTmean-max, and ~14.5% in CC-IMTmax. In IMPROVE women, LLAS explained 0.3–0.4% of variance. R46L (rs11591147-T) was significantly associated with CC-IMT variables in UKB. No significant sex or lipid-lowering medication interactions. Meta-analysis (n=43,404) showed consistent negative but modest effects. Absolute risk differences were not reported because the outcome was continuous CC-IMT, not clinical events.
Confidence Level
Moderate. Strengths: two cohorts, large UKB sample, genetic instruments, meta-analysis. Limitations: cross-sectional, no incident CVD outcomes, modest effects, inconsistent sex-specific findings, only two studies in meta-analysis, UKB healthy-volunteer bias, self-reported medication. Not retracted; no corrections reported.
Study Flags
Red Flags
- •Cross-sectional design; cannot establish causality or incident CVD risk
- •Modest effects and inconsistent sex-specific findings; no significant interaction
- •UK Biobank healthy-volunteer bias and self-reported medication; meta-analysis only two studies
Surprising Findings
The same PCSK9 genetic score explained ~20% of CC-IMT variance in UK Biobank but only 0.3–0.4% in IMPROVE women.
A 20% variance explained by four common variants is extremely high for a complex trait like artery thickness, while 0.3% is more typical for a polygenic score. The discrepancy suggests model or measurement differences.
Practical Takeaways
Don't rush to get PCSK9 genetic testing to predict your heart risk — focus on proven factors like blood pressure, smoking, and LDL cholesterol.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Moderate probability
on the GRADE evidence scale
This study looked at whether certain gene variations are linked to thinner neck arteries, which can mean less heart disease risk. But because it's not a randomized experiment, it can only show a connection, not prove that the genes directly cause the change.
Strengths
- Large sample size (n=52,128 total).
- Two independent cohorts (IMPROVE and UKB).
- Use of genetic variants reduces confounding by environmental factors.
Weaknesses
- Cross-sectional design cannot establish causality.
- Modest effect sizes; not all variants reached statistical significance.
- Only European ancestry participants, limiting generalizability.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists looked at four tiny gene changes in PCSK9 that lower cholesterol. They checked whether people with more of these changes had thinner carotid arteries.
Research results
People with more cholesterol-lowering PCSK9 gene changes tended to have slightly thinner carotid artery walls. In UK Biobank, the combined gene score was linked to thinner arteries (p<0.05) and reportedly explained about 20% of the variation in one measure; in IMPROVE, the link was seen in women but not men (p<0.05) and explained 0.3–0.4% of variation. The R46L variant was linked to thinner arteries in UK Biobank. No extra-cases-per-1,000 absolute risk was reported because this measured artery thickness, not heart attacks.
What this means - more context
This is about small differences in artery wall thickness, not heart attacks or deaths. The study did not report absolute risk (like extra cases per 1,000 people) because it did not count disease events. So we cannot say how many heart attacks might be prevented.
Investigated whether genetically determined LDL-C levels, proxied by four PCSK9 variants, influence common carotid artery atherosclerosis (CC-IMT) in a high-CVD-risk cohort (IMPROVE) and a general-population cohort (UK Biobank).
In cross-sectional analyses, a PCSK9 lipid-lowering allelic score (LLAS) was negatively associated with CC-IMT in IMPROVE women and in UKB men/overall (p<0.05), with consistent negative effect estimates in a fixed-effects meta-analysis (n=43,404). R46L (rs11591147-T) was associated with CC-IMT in UKB. Effects were modest and did not differ significantly by sex or lipid-lowering medication. The study did not report absolute risk because outcomes were continuous artery-wall measures. No retraction or corrections reported.
Methods Used
Observational genetic association study: 3,040 European high-CVD-risk IMPROVE participants and 49,088 white British UK Biobank participants; four PCSK9 variants genotyped and combined into an unweighted LLAS; carotid ultrasound measured CC-IMTmean, CC-IMTmax, CC-IMTmean-max; linear regression adjusted for age, sex, population structure, and lipid-lowering medication; fixed-effects meta-analysis of two cohorts.
Main Finding
The LLAS was negatively associated with all CC-IMT measures in IMPROVE women but not men, and in UKB men and overall (p<0.05); in UKB, LLAS reportedly explained ~20% of variance in CC-IMTmean (R2=0.193), ~18.7% in CC-IMTmean-max, and ~14.5% in CC-IMTmax. In IMPROVE women, LLAS explained 0.3–0.4% of variance. R46L (rs11591147-T) was significantly associated with CC-IMT variables in UKB. No significant sex or lipid-lowering medication interactions. Meta-analysis (n=43,404) showed consistent negative but modest effects. Absolute risk differences were not reported because the outcome was continuous CC-IMT, not clinical events.
Confidence Level
Moderate. Strengths: two cohorts, large UKB sample, genetic instruments, meta-analysis. Limitations: cross-sectional, no incident CVD outcomes, modest effects, inconsistent sex-specific findings, only two studies in meta-analysis, UKB healthy-volunteer bias, self-reported medication. Not retracted; no corrections reported.
Study Flags
Red Flags
- •Cross-sectional design; cannot establish causality or incident CVD risk
- •Modest effects and inconsistent sex-specific findings; no significant interaction
- •UK Biobank healthy-volunteer bias and self-reported medication; meta-analysis only two studies
Surprising Findings
The same PCSK9 genetic score explained ~20% of CC-IMT variance in UK Biobank but only 0.3–0.4% in IMPROVE women.
A 20% variance explained by four common variants is extremely high for a complex trait like artery thickness, while 0.3% is more typical for a polygenic score. The discrepancy suggests model or measurement differences.
Practical Takeaways
Don't rush to get PCSK9 genetic testing to predict your heart risk — focus on proven factors like blood pressure, smoking, and LDL cholesterol.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Moderate probability
on the GRADE evidence scale
This study looked at whether certain gene variations are linked to thinner neck arteries, which can mean less heart disease risk. But because it's not a randomized experiment, it can only show a connection, not prove that the genes directly cause the change.
Strengths
- Large sample size (n=52,128 total).
- Two independent cohorts (IMPROVE and UKB).
- Use of genetic variants reduces confounding by environmental factors.
Weaknesses
- Cross-sectional design cannot establish causality.
- Modest effect sizes; not all variants reached statistical significance.
- Only European ancestry participants, limiting generalizability.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study used a very large number of people from two different groups, which makes the results more reliable. However, it only looked at people of European ancestry and measured arteries at one point in time, so we can't be sure about cause and effect.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=52128)+20/20
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. Cross-sectional design cannot establish temporal or causal relationships. Although genetic variants are randomly assigned at conception, the study is observational and cannot rule out pleiotropy, population stratification, or residual confounding. It does not use formal Mendelian randomization with instrumental variable assumptions.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding statement was included in the provided text, so potential conflicts cannot be assessed.
The provided manuscript excerpt lacks a COI/funding section. No author affiliations or industry ties are evident. The study uses public cohorts (IMPROVE, UK Biobank) and commercial ELISA kits, but no industry funding is disclosed. Absence of funding statement limits transparency.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
25 researchersIf this is your work, this is how we attribute it on Fit Body Science. Daniela Coggi is listed as the lead author.